Description of (re-)induction therapies prior to a planned stem cell transplantation in patients with relapsed / refractory multiple myeloma in Germany

• Conditions: C90.0; Multiple myeloma

• Registration Number: DRKS00026023
• Lead Sponsor: AMGEN (Europe) GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-07
• Study Completion: 2022-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 187

Inclusion Criteria

Patient aged 18 years or older at index date*
- Patient with diagnosis of MM histologically or cytologically confirmed as defined according to IMWG
- Patient had already received at least one therapy for MM and then relapsed or was refractory to initial therapy after initial response
- Patient was planned to receive myeloablative conditioning and SCT in second or third line based on assessment at index date*
- Start date of (re-)induction therapy (index date*) was within the period from January 2016 to December 2019
- Patient had completed a (re-)induction therapy in second or third line (index therapy)

*Index date is defined as start of (re-)induction therapy for a planned myeloablative conditioning and SCT in second or third line.

Exclusion Criteria

- Patient not eligible for SCT based on physician’s assessment prior to start of (re )induction therapy in second or third line.
- Patient did not complete (re-)induction therapy in second or third line.

Study & Design

• Study Type: observational
• Study Design: Not specified